Zevra Therapeutics sells SDX portfolio to Commave for $50M

Zevra Therapeutics (ZVRA) announced an agreement under which Commave Therapeutics will purchase Zevra’s serdexmethylphenidate portfolio, including AZSTARYS and KP1077, for $50 million. Zevra and Commave had previously entered into a 2019 license agreement under which Zevra granted Commave an exclusive license to certain SDX products. In 2024, Commave initiated litigation in Delaware Chancery Court against Zevra, and as part of today’s purchase agreement between the companies, the parties mutually agreed to settle the dispute. Prior to entering into the agreement, the Company repaid the principal balance on its $63 million term loan in full, resulting in a strong, debt-free balance sheet and enhanced financial and strategic flexibility.